FDA Approves Merck's Improved HPV Vax

Dec 11, 2014

FDA

Merck & Co. has received FDA approval for Gardasil 9, a new vaccine that provides broader protection than Merck's previously approved Gardasil against HPV-related cancers.

Covering nine HPV types, five more HPV types than Merck's Gardasil, Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.

Analysts predict the new vaccine could bring Merck as much as $1.9 billion a year, but much of its market share will come at Gardasil's expense.

Read the FDA press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments